Cervical cancer prevention relies on two different age-specific technologies, and consumers should not be misled about the role of HPV vaccines
The introduction of human papillomavirus (HPV) vaccines to clinical practice is the end result of a remarkable distillation of basic science, new technology, epidemiological understanding, clinical research and commercial development. It has brought together stakeholders from a variety of backgrounds to consider these developments, and Australia is now the first country to implement a population-based mass vaccination program against HPV. The Australian HPV vaccination program was commenced after cost-effectiveness of the quadrivalent vaccine was demonstrated,1 anticipating that the expected reduction in the cost of treating HPV-related disease in Australian women would compensate for the cost of the vaccine. This program, an Australian Government initiative,2 appears to have been very successful in terms of coverage, and offers young Australian women the opportunity to be among the first national cohort to be vaccinated against the virus types that cause most cervical cancers and a variety of other HPV-related diseases.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Kulasingam S, Connelly L, Conway E, et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health 2007; 4: 165–175.
- 2. Australian Government Department of Health and Ageing. The national HPV vaccination program. http://www.health.gov.au/internet/standby/publishing.nsf/Content/about (accessed Sep 2007).
- 3. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157: 218-226.
- 4. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006; 24 Suppl 3: S106-S113.
- 5. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
- 6. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III, double-blind, randomised controlled trial. Lancet 2007; 369: 2161-2170.
- 7. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005; 32 Suppl 1: S7-S15.
- 8. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298: 743-753.
- 9. Luna J. The safety, efficacy and immunogenicity of quadrivalent HPV (types 6/11/16/18) L1 virus-like-particle (VLP) vaccine in women aged 24 to 45. Proceedings of the 24th International Papillomavirus Conference and Clinical Workshop; 2007 Nov 3-9; Beijing, China.
- 10. Australian Government Department of Health and Ageing. Pharmaceutical Benefits Advisory Committee outcomes by meeting. July 2007 PBAC outcomes — “1st time” decisions not to recommend. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/pbacrec-july07-1st_time (accessed Sep 2007).
- 11. Australian Government Department of Health and Ageing. Pharmaceutical Benefits Advisory Committee outcomes by meeting. Positive recommendations made by the PBAC — November 2007. http://www.health.gov.au/internet/main/publishing.nsf/Content/pbacrec-Nov07-positive (accessed Sep 2007).
- 12. GlaxoSmithKline. Now you can help protect women over 26 against cervical cancer [advertisement]. O & G Magazine 2007; 9: 3.
- 13. Australian Government Department of Health and Ageing. Regulation of therapeutic goods in Australia. http://www.tga.gov.au/docs/html/tga/tgaginfo.htm (accessed Sep 2007).
- 14. World Health Organization. Expert Committee on Biological Standardization. Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines. Geneva: WHO, 2006. http://www.who.int/biologicals/publications/trs/areas/vaccines/human_papillomavirus/HPVg%20Final%20BS%202050%20.pdf (accessed Apr 2008).
I am the Chair of the CSL Gardasil Advisory Board. I have received speaker fees, travel assistance and consultancy fees from CSL Biotherapies and from Merck and its affiliates in relation to Gardasil. I hold shares in CSL Limited.